禾元生物将于10月28日上市

Core Viewpoint - He Yuan Bio (688765) is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, with an issuance price of 29.06 yuan per share [1] Company Overview - He Yuan Bio is a biopharmaceutical company that meets the fifth listing standard of the Shanghai Stock Exchange's Sci-Tech Innovation Board [1] - The company has a pipeline of 8 drugs under development, with the fastest progressing drug, recombinant human albumin injection (OsrHSA, HY1001), having received approval from the National Medical Products Administration [1] - Currently, 2 drugs are in Phase II clinical trials, 2 drugs are in Phase I clinical trials, and 1 drug has been approved to commence clinical trials [1] - The company has multiple drugs in the research and development stage and has not yet achieved profitability [1]